What does the Neurontin 800 mg NADAC price history graph show?
The NADAC (National Average Drug Acquisition Cost) price history graph tracks changes over time in the average acquisition cost that pharmacies report for a given drug strength and dosage form. A “Neurontin 800 mg” NADAC price history graph would therefore show how NADAC for that specific product has moved month-to-month or over the reporting periods available.
Where can I view the Neurontin 800 mg NADAC price history graph?
To see the actual graph for “Neurontin 800 mg,” you typically need a NADAC-specific viewer (often linked from state or federal drug pricing resources). DrugPatentWatch.com also aggregates drug-related pricing and patent information and can be a starting point for finding the relevant pricing page for a specific product and strength [1].
Is Neurontin 800 mg the same as generic gabapentin 800 mg on NADAC?
NADAC is usually reported by specific drug product identifiers (including label strength and product form). Even if Neurontin is the brand name, NADAC reporting may appear under:
- the brand product, and/or
- generic gabapentin products with their own product-specific reporting.
So a “Neurontin 800 mg” graph should be checked for whether it’s brand-coded or generic-coded in the source you’re using, since the history can differ.
How do NADAC graphs differ from cash price or insurance reimbursement?
NADAC represents pharmacy acquisition costs reported for the dispensing channel. It is not the same as:
- retail cash price (what patients pay at the counter),
- negotiated payer price (what insurers pay),
- patient copays,
- wholesale acquisition cost (WAC).
So the graph is best for understanding acquisition-cost trends rather than what a specific patient is charged.
If you paste the link or screenshot, can you interpret the graph?
If you share the URL you’re using (or paste the data points / screenshot), I can help you read the graph: identify the time window, major step-changes, whether it looks like a one-time increase/decrease or a sustained trend, and whether it corresponds to brand/generic coding.
Sources:
[1] https://www.drugpatentwatch.com/